Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: A randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 17, Issue 1, 2015, Pages 82-90

  Hompesch, M ^a   Jones Leone, A ^b   Carr, M C ^b   Matthews, J ^b   Zhi, H ^b   Young, M ^b   Morrow, L ^a   Reinhardt, R R ^b  

^a Profil Institute for Clinical Research Inc   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

GLP 1 analogue; Glucose metabolism; Type 2 diabetes mellitus

Indexed keywords

ADRENALIN; ALBIGLUTIDE; C PEPTIDE; GLUCAGON; GLUCOSE; GROWTH HORMONE; HORMONE; HYDROCORTISONE; INSULIN; NORADRENALIN; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; RECOMBINANT PROTEIN; RGLP-1 PROTEIN;

AREA UNDER THE CURVE; ARTICLE; BACKACHE; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UPPER ABDOMINAL PAIN; ADULT; AGONISTS; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOWN REGULATION; DRUG EFFECTS; GENETICS; GLUCOSE CLAMP TECHNIQUE; HYPERGLYCEMIA; MIDDLE AGED; PANCREAS; SECRETION (PROCESS); UPREGULATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PANCREAS; RECOMBINANT PROTEINS; UP-REGULATION;

EID: 84919471396     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12398     Document Type: Article

References (30)

1. Surampudi PN, John-Kalarickal J, Fonseca VA. Emerging concepts in the pathophysiology of type 2 diabetes mellitus. Mt Sinai J Med 2009; 76: 216-226.
2. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(Suppl. 1): S14-80.
3. Bolen S, Wilson L, Vassy J et al. Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Comparative Effectiveness Review No. 8. (Prepared by Johns Hopkins Evidence-based Practice Center under Contract No. 290-02-0018.) Rockville, MD: Agency for Healthcare Research and Quality. Available from URL: http://www.effectivehealthcare.ahrq.gov/ehc/assets/File/OralFullReport.pdf. Accessed 25 November 2013.
4. Vouyiouklis M. Canagliflozin: improving diabetes by making urine sweet. Cleve Clin J Med 2013; 80: 683-687.
5. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33: 428-433.
6. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
7. Fu AZ, Qiu Y, Radican L, Yin DD, Mavros P. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study. Cardiovasc Diabetol 2010; 9: 15.
8. Vinagre I, Mata-Cases M, Hermosilla E et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care 2012; 35: 774-779.
9. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10-18.
10. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
11. Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep 2010; 10: 124-132.
12. Matthews JE, Stewart MW, De Boever EH et al. Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting GLP-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 4810-4817.
13. Bush MA, Matthews JE, De Boever EH et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009; 11: 498-505.
14. Rosenstock J, Stewart MW. Albiglutide: glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes. Drug Future 2010; 35: 701-712.
15. Reusch J, Stewart M, Perkins C et al. HARMONY 1 results at week 52 primary endpoint: once-weekly albiglutide vs placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone±metformin. Diabetologia 2013; 56(Suppl. 1): S359-360.
16. Reinhardt R, Nauck MA, Stewart M et al. HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia 2013; 56(Suppl. 1): S360.
17. Ahrén B, Johnson SL, Stewart M et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 2014; 37: 2141-2148.
18. Pratley R, Stewart M, Cirkel D, Ye J, Perry C, Carr MC. HARMONY 4: 52-week efficacy of albiglutide vs insulin glargine in patients with type 2 diabetes mellitus. Diabetologia 2013; 56(Suppl. 1): S360-361.
19. Stewart M, Home P, Yang F, Perry C, Carr MC. 52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study. Diabetologia 2013; 56(Suppl. 1): S361.
20. Rosenstock J, Fonseca V, Gross JL et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist versus thrice daily prandial insulin lispro. Diabetes Care 2014; 37: 2317-2325.
21. Pratley RE, Nauck MA, Barnett AH et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 289-297.
22. Leiter LA, Carr MC, Stewart M, Jones-Leone A, Yang F, Handelsman Y. HARMONY 8: once-weekly glucagon-like peptide 1 receptor agonist albiglutide vs sitagliptin for patients with type 2 diabetes with renal impairment: week 26 results. Diabetologia 2013; 56(Suppl. 1): S361-362.
23. Polonsky KS, Licinio-Paixao J, Given BD et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 1986; 77: 98-105.
24. Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.
25. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 1980; 51: 520-528.
26. Nauck MA, El-Ouaghlidi A, Hompesch M, Jacobson J, Elbrond B. No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes. Diabetes 2003; 52(Suppl. 1): A128.
27. Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397-2403.
28. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
29. Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus: paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest 1984; 73: 1532-1541.
30. Davis SN, Fowler S, Costa F. Hypoglycemic counterregulatory responses differ between men and women with type 1 diabetes. Diabetes 2000; 49: 65-72.